What is EpiBone?
EpiBone is at the forefront of regenerative medicine, focusing on creating patient-specific bone and cartilage constructs using stem cell technology. Their innovative bioreactor system facilitates the growth of a patient's own cells into functional skeletal tissue, addressing the root causes of pain and mobility issues. This regenerative healing approach is particularly targeted towards younger, active individuals seeking long-term solutions rather than temporary fixes for skeletal conditions. The company's mission is to transform the treatment landscape for skeletal ailments by providing natural, regenerative therapies.
How much funding has EpiBone raised?
EpiBone has raised a total of $5.3M across 4 funding rounds:
Private Equity
$560K
Debt
$150K
Debt
$341K
Private Equity
$4.3M
Private Equity (2016): $560K with participation from Plum Alley
Debt (2020): $150K led by PPP
Debt (2021): $341K supported by PPP
Private Equity (2025): $4.3M, investors not publicly disclosed
Key Investors in EpiBone
Plum Alley
Plum Alley Ventures is a venture firm that facilitates smart investments in breakthrough technologies aimed at improving the world for humans, industry, and the planet. The company focuses on providing access to well-vetted investment opportunities for a diverse range of investors, enabling them to participate in the technological revolution.
What's next for EpiBone?
With substantial enterprise-level backing and a recent strategic investment, EpiBone is well-positioned for accelerated growth and market penetration. The company's focus on regenerative therapies for skeletal conditions, utilizing its unique stem cell and bioreactor technology, aligns with a growing demand for personalized and effective medical solutions. Future developments are likely to involve scaling production capabilities, expanding clinical trials, and forging strategic partnerships to bring their innovative treatments to a wider patient population. This significant capital infusion will fuel research and development, further solidifying EpiBone's leadership in the field of tissue engineering and regenerative medicine.
See full EpiBone company page
